Skip to main content
Top
Gepubliceerd in:

25-10-2021

The Effect of Cognitive-Behavioral Therapy Versus Duloxetine on the Laboratory Indices of Inflammation in Fibromyalgia: A Randomized Controlled Trial

Auteurs: Mozhdeh Zabihiyeganeh, Azade Amini Kadijani, Sedigheh Vafaee Afshar, Masoud Janbozorgi, Abolfazl Akbari, Alireza Mirzaei

Gepubliceerd in: Journal of Rational-Emotive & Cognitive-Behavior Therapy | Uitgave 3/2022

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Proinflammatory cytokines have been introduced as surrogate markers of inflammation in fibromyalgia (FM). In this study, we aimed to evaluate the effect of cognitive-behavioral therapy (CBT) versus duloxetine on the serum levels of candidate cytokines, besides their impact on the clinical outcome measures. A total of 128 patients were randomized to either CBT or duloxetine group, 64 patients each. For the CBT group, traditional face-to-face CBT was offered in twice-weekly sessions over ten weeks. For the duloxetine group, the treatment was started with 30 mg/day duloxetine and continued with 60 mg/day duloxetine after a week, up to 10 weeks. The primary outcome measures were the serum levels of IL-6, IL-8, and TNFα. Secondary outcome measures were the fibromyalgia impact questionnaire (FIQ) and the widespread pain index (WPI). Fifty-two patients in the CBT group and 53 patients in the duloxetine group completed the study. No significant difference was observed between the baseline characteristics of the two study groups. All the outcome measures were significantly improved after the intervention in both study groups. No significant difference was observed between the two study groups regarding the mean change of IL-6, IL-8, TNFα, FIQ, and WPI (p = 0.43, p = 0.85, p = 0.91, p = 0.8, and p = 0.67, respectively, Intention-to-treat analysis). Therefore, CBT can be selected as an alternative for duloxetine in the treatment of FM symptoms, particularly in patients with duloxetine intolerance. However, patients’ motivation should be taken into account before selecting CBT as the treatment of choice.
Trial registration number and date of registration: IRCT2016120530871N3, 2016-12-18.
Literatuur
go back to reference Alda, M., Luciano, J. V., Andrés, E., Serrano-Blanco, A., Rodero, B., del Hoyo, Y. L., et al. (2011). Effectiveness of cognitive behaviour therapy for the treatment of catastrophisation in patients with fibromyalgia: A randomised controlled trial. Arthritis Research & Therapy, 13(5), R173.CrossRef Alda, M., Luciano, J. V., Andrés, E., Serrano-Blanco, A., Rodero, B., del Hoyo, Y. L., et al. (2011). Effectiveness of cognitive behaviour therapy for the treatment of catastrophisation in patients with fibromyalgia: A randomised controlled trial. Arthritis Research & Therapy, 13(5), R173.CrossRef
go back to reference Ang, D. C., Chakr, R., Mazzuca, S., France, C. R., Steiner, J., & Stump, T. (2010). Cognitive-behavioral therapy attenuates nociceptive responding in patients with fibromyalgia: A pilot study. Arthritis Care Res (hoboken), 62(5), 618–623.CrossRef Ang, D. C., Chakr, R., Mazzuca, S., France, C. R., Steiner, J., & Stump, T. (2010). Cognitive-behavioral therapy attenuates nociceptive responding in patients with fibromyalgia: A pilot study. Arthritis Care Res (hoboken), 62(5), 618–623.CrossRef
go back to reference Arnold, L. M., Clauw, D. J., Wohlreich, M. M., Wang, F., Ahl, J., Gaynor, P. J., & Chappell, A. S. (2009). Efficacy of duloxetine in patients with fibromyalgia: Pooled analysis of 4 placebo-controlled clinical trials. Primary Care Companion to the Journal of Clinical Psychiatry, 11(5), 237–244.CrossRef Arnold, L. M., Clauw, D. J., Wohlreich, M. M., Wang, F., Ahl, J., Gaynor, P. J., & Chappell, A. S. (2009). Efficacy of duloxetine in patients with fibromyalgia: Pooled analysis of 4 placebo-controlled clinical trials. Primary Care Companion to the Journal of Clinical Psychiatry, 11(5), 237–244.CrossRef
go back to reference Association, A. P. (2013). Diagnostic and statistical manual of mental disorders. BMC Medicine, 17, 133–137. Association, A. P. (2013). Diagnostic and statistical manual of mental disorders. BMC Medicine, 17, 133–137.
go back to reference Bennett, R. M., Jones, J., Turk, D. C., Russell, I. J., & Matallana, L. (2007). An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders, 8, 27.CrossRef Bennett, R. M., Jones, J., Turk, D. C., Russell, I. J., & Matallana, L. (2007). An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders, 8, 27.CrossRef
go back to reference Bernardy, K., Klose, P., Welsch, P., & Häuser, W. (2018). Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome—A systematic review and meta-analysis of randomized controlled trials. European Journal of Pain, 22(2), 242–260.CrossRef Bernardy, K., Klose, P., Welsch, P., & Häuser, W. (2018). Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome—A systematic review and meta-analysis of randomized controlled trials. European Journal of Pain, 22(2), 242–260.CrossRef
go back to reference Castel, A., Salvat, M., Sala, J., & Rull, M. (2009). Cognitive-behavioural group treatment with hypnosis: A randomized pilot trail in fibromyalgia. Contemporary Hypnosis, 26(1), 48–59.CrossRef Castel, A., Salvat, M., Sala, J., & Rull, M. (2009). Cognitive-behavioural group treatment with hypnosis: A randomized pilot trail in fibromyalgia. Contemporary Hypnosis, 26(1), 48–59.CrossRef
go back to reference Edinger, J. D., Wohlgemuth, W. K., Krystal, A. D., & Rice, J. R. (2005). Behavioral insomnia therapy for fibromyalgia patients: A randomized clinical trial. Archives of Internal Medicine, 165(21), 2527–2535.CrossRef Edinger, J. D., Wohlgemuth, W. K., Krystal, A. D., & Rice, J. R. (2005). Behavioral insomnia therapy for fibromyalgia patients: A randomized clinical trial. Archives of Internal Medicine, 165(21), 2527–2535.CrossRef
go back to reference Free, M. L. (2007). Cognitive therapy in groups: Guidelines and resources for practice. Wiley. Free, M. L. (2007). Cognitive therapy in groups: Guidelines and resources for practice. Wiley.
go back to reference Ghassemzadeh, H., Mojtabai, R., Karamghadiri, N., & Ebrahimkhani, N. (2005). Psychometric properties of a Persian-language version of the Beck Depression Inventory-Second edition: BDI-II-PERSIAN. Depression Anxiety, 21(4), 185–192.CrossRef Ghassemzadeh, H., Mojtabai, R., Karamghadiri, N., & Ebrahimkhani, N. (2005). Psychometric properties of a Persian-language version of the Beck Depression Inventory-Second edition: BDI-II-PERSIAN. Depression Anxiety, 21(4), 185–192.CrossRef
go back to reference Kaviani, H., & Mousavi, A. (2008). Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). Tehran University Medical Journal, 66(2), 136–140. Kaviani, H., & Mousavi, A. (2008). Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). Tehran University Medical Journal, 66(2), 136–140.
go back to reference Kia, S., & Choy, E. (2017). Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines, 5(2), 20.CrossRef Kia, S., & Choy, E. (2017). Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines, 5(2), 20.CrossRef
go back to reference Kosek, E., Altawil, R., Kadetoff, D., Finn, A., Westman, M., Le Maître, E., et al. (2015). Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain—Interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis. Journal of Neuroimmunology, 280, 49–55.CrossRef Kosek, E., Altawil, R., Kadetoff, D., Finn, A., Westman, M., Le Maître, E., et al. (2015). Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain—Interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis. Journal of Neuroimmunology, 280, 49–55.CrossRef
go back to reference Lian, Y. N., Wang, Y., Zhang, Y., & Yang, C. X. (2020). Duloxetine for pain in fibromyalgia in adults: A systematic review and a meta-analysis. International Journal of Neuroscience, 130(1), 71–82.CrossRef Lian, Y. N., Wang, Y., Zhang, Y., & Yang, C. X. (2020). Duloxetine for pain in fibromyalgia in adults: A systematic review and a meta-analysis. International Journal of Neuroscience, 130(1), 71–82.CrossRef
go back to reference Malin, K., & Littlejohn, G. O. (2012). Personality and fibromyalgia syndrome. Open Rheumatology Journal, 6, 273–285.CrossRef Malin, K., & Littlejohn, G. O. (2012). Personality and fibromyalgia syndrome. Open Rheumatology Journal, 6, 273–285.CrossRef
go back to reference Mirzaei, A., Zabihiyeganeh, M., Jahed, S. A., Khiabani, E., Nojomi, M., & Ghaffari, S. (2018). Effects of vitamin D optimization on quality of life of patients with fibromyalgia: A randomized controlled trial. Medical Journal of the Islamic Republic of Iran, 32, 29.CrossRef Mirzaei, A., Zabihiyeganeh, M., Jahed, S. A., Khiabani, E., Nojomi, M., & Ghaffari, S. (2018). Effects of vitamin D optimization on quality of life of patients with fibromyalgia: A randomized controlled trial. Medical Journal of the Islamic Republic of Iran, 32, 29.CrossRef
go back to reference Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(2), 16.CrossRef Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(2), 16.CrossRef
go back to reference Parra-Delgado, M., & Latorre-Postigo, J. M. (2013). Effectiveness of mindfulness-based cognitive therapy in the treatment of fibromyalgia: A randomised trial. Cognitive Therapy and Research, 37(5), 1015–1026.CrossRef Parra-Delgado, M., & Latorre-Postigo, J. M. (2013). Effectiveness of mindfulness-based cognitive therapy in the treatment of fibromyalgia: A randomised trial. Cognitive Therapy and Research, 37(5), 1015–1026.CrossRef
go back to reference Queiroz, L. P. (2013). Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports, 17(8), 356.CrossRef Queiroz, L. P. (2013). Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports, 17(8), 356.CrossRef
go back to reference Randall, C. L., & McNeil, D. W. (2017). Motivational interviewing as an adjunct to cognitive behavior therapy for anxiety disorders: A critical review of the literature. Cognitive and Behavioral Practice, 24(3), 296–311.CrossRef Randall, C. L., & McNeil, D. W. (2017). Motivational interviewing as an adjunct to cognitive behavior therapy for anxiety disorders: A critical review of the literature. Cognitive and Behavioral Practice, 24(3), 296–311.CrossRef
go back to reference Rosenman, R., Tennekoon, V., & Hill, L. G. (2011). Measuring bias in self-reported data. International Journal of Behavioural and Healthcare Research, 2(4), 320–332.CrossRef Rosenman, R., Tennekoon, V., & Hill, L. G. (2011). Measuring bias in self-reported data. International Journal of Behavioural and Healthcare Research, 2(4), 320–332.CrossRef
go back to reference Scholz, B. A., Hammonds, C. L., & Boomershine, C. S. (2009). Duloxetine for the management of fibromyalgia syndrome. Journal of Pain Research, 2, 99.PubMedPubMedCentral Scholz, B. A., Hammonds, C. L., & Boomershine, C. S. (2009). Duloxetine for the management of fibromyalgia syndrome. Journal of Pain Research, 2, 99.PubMedPubMedCentral
go back to reference Shooshtari, M. H., Davari-Ashtiani, R., Shahrivar, Z., Shabani, A., Semnani, Y., Kaviani, H., et al. (2007). Structured clinical interview for DSM-IV (SCID Persian translation and cultural adaptation). Iranian Journal of Psychiatry, 2(1), 46–48. Shooshtari, M. H., Davari-Ashtiani, R., Shahrivar, Z., Shabani, A., Semnani, Y., Kaviani, H., et al. (2007). Structured clinical interview for DSM-IV (SCID Persian translation and cultural adaptation). Iranian Journal of Psychiatry, 2(1), 46–48.
go back to reference Staud, R., & Smitherman, M. L. (2002). Peripheral and central sensitization in fibromyalgia: Pathogenetic role. Current Pain and Headache Reports, 6(4), 259–266.CrossRef Staud, R., & Smitherman, M. L. (2002). Peripheral and central sensitization in fibromyalgia: Pathogenetic role. Current Pain and Headache Reports, 6(4), 259–266.CrossRef
go back to reference Wilson, E., & Lader, M. (2015). A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology, 5(6), 357–368.CrossRef Wilson, E., & Lader, M. (2015). A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology, 5(6), 357–368.CrossRef
go back to reference Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Häuser, W., Katz, R. L., et al. (2016). 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Paper presented at the Seminars in Arthritis and Rheumatism. Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Häuser, W., Katz, R. L., et al. (2016). 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Paper presented at the Seminars in Arthritis and Rheumatism.
go back to reference Wright, C. L., Mist, S. D., Ross, R. L., & Jones, K. D. (2010). Duloxetine for the treatment of fibromyalgia. Expert Review of Clinical Immunology, 6(5), 745–756.CrossRef Wright, C. L., Mist, S. D., Ross, R. L., & Jones, K. D. (2010). Duloxetine for the treatment of fibromyalgia. Expert Review of Clinical Immunology, 6(5), 745–756.CrossRef
go back to reference Zabihiyeganeh, M., Afshar, S. V., Kadijani, A. A., Jafari, D., Bagherifard, A., Janbozorgi, M., et al. (2019). The effect of cognitive behavioral therapy on the circulating proinflammatory cytokines of fibromyalgia patients: A pilot controlled clinical trial. General Hospital Psychiatry, 57, 23–28.CrossRef Zabihiyeganeh, M., Afshar, S. V., Kadijani, A. A., Jafari, D., Bagherifard, A., Janbozorgi, M., et al. (2019). The effect of cognitive behavioral therapy on the circulating proinflammatory cytokines of fibromyalgia patients: A pilot controlled clinical trial. General Hospital Psychiatry, 57, 23–28.CrossRef
Metagegevens
Titel
The Effect of Cognitive-Behavioral Therapy Versus Duloxetine on the Laboratory Indices of Inflammation in Fibromyalgia: A Randomized Controlled Trial
Auteurs
Mozhdeh Zabihiyeganeh
Azade Amini Kadijani
Sedigheh Vafaee Afshar
Masoud Janbozorgi
Abolfazl Akbari
Alireza Mirzaei
Publicatiedatum
25-10-2021
Uitgeverij
Springer US
Gepubliceerd in
Journal of Rational-Emotive & Cognitive-Behavior Therapy / Uitgave 3/2022
Print ISSN: 0894-9085
Elektronisch ISSN: 1573-6563
DOI
https://doi.org/10.1007/s10942-021-00426-y